Debra BorchardtDebra BorchardtJanuary 6, 2020


Hightimes Holding Corp. told investors that it accepted the resignation of Kraig G. Fox as the Company’s Chief Executive Officer and President Effective December 24, 2019. On January 6, 2020, Stormy Simon, one of the Company’s independent directors and former President of Overstock.com Inc., was appointed to the position of Chief Executive Officer of the company by the board of directors. Following her appointment, she will also continue serving as a director on the Company’s board of directors.

Stormy Simon

The change is happening as the cannabis publication prepares to develop its physical and virtual distribution businesses. Having spent the last year acquiring Cannabis media publications and web sites, High Times now looks to monetize its audience of millions of users across the globe. Fox was just hired in April with the intent to finally bring the company public, a move that has been discussed for years at this point. Instead, the launch of the publicly traded stock got delayed again. Fox’s background as a Senior Managing Director of Guggenheim Partners where he focused on Guggenheim’s overall strategy in the media and entertainment spaces as well as the management of its media and entertainment investments was seen as an asset.

Fox was also a founder and Chief Operating Officer of Core Media (previously CKX, Inc.) where he oversaw all operations of this publicly-traded company including Core’s interests in the estate of Elvis Presley and the intellectual property rights of Muhammad Ali as well oversight of its wholly-owned subsidiary, 19 Entertainment, which included American Idol (including television, records, lives tours, artist management and sponsorships) and So You Think You Can Dance. It was anticipated he would capitalize on the name brand of High Times through licensing deals.

Recently, Fox had suggested the company would pivot into consumption cafes and dispensaries and away from cannabis content. Now, it seems there is another pivot away from that idea and Fox has left.

“I’m honored to take on this role at such a pivotal time for this iconic brand. The cost of customer acquisition has plagued the cannabis industry thus far, but utilizing the High Times brand’s global audience, we should be able to monetize our traffic by connecting consumers to cannabis products at an unprecedented scale,” Stormy Simon stated. “Like millions of other people, I have trusted High Times for years and I can’t wait to use my experience to help develop the next iteration of our business: delivering the best products into consumers’ hands.”

Levin will remain in his role as Executive Chairman. He said, “Stormy Simon, who rose through the ranks at Overstock.com during her 15-year tenure with the company, has extensive international business relations and marketing experience and is highly skilled at breaking down and rebuilding departments. Stormy revolutionized Overstock.com’s marketing department, and then its customer service department, during an uncharted time in e-commerce history, eventually leading Overstock.com to increase its revenues from $20 million to over $2 Billion.”


According to the company’s filings, Ms. Simon will receive a base salary of $300,000 per year, payable in equal monthly installments, provided that the Base Salary shall initially be fixed at $215,000 and the remainder of the Base Salary shall accrue until, and be payable at, such time as the Company shall have raised an additional $10 million. In addition to the salary, Simon will get an annual bonus of up to $225,000 for each calendar year of her employment with the company depending on the High Times’ ability to achieve certain performance goals.  She will also have an option to buy 200,000 shares of common stock at an exercise price of $11.00 per share. One-third of those options vest on January 6, 2020, and the balance of such option shares vesting in equal monthly increments over the remaining two year period.

Simon will also receive a $3,000 travel stipend for company travel between San Jose and Los Angeles for the first six months of employment.

Fox will continue to receive his director and officer insurance policy, and High Times agreed to reimburse Mr. Fox for certain previously incurred business expenses (within five days) of successful completion of sales of an additional $5 million of equity securities or $10 million of proceeds from the sale of debt securities. He is expected to be reimbursed $125,000 with respect to expenses and lease payments for which Fox provided the company with receipts.






Debra BorchardtDebra BorchardtJanuary 6, 2020


The Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) announced that its Board of Directors has named Colin Moore, Director of the Company and former President of Starbucks Coffee Canada, as Interim President and Chief Executive Officer, effective immediately. Mr. Moore succeeds Navdeep Dhaliwal, who has departed the Company.

Supreme recent reported a drop in its revenue from the 2019 fourth quarter amount of $19 million to the  2020 first quarter amount of $11.4 million. The quarter-over-quarter decrease in net revenue was attributed to the combination of a rapid deterioration of pricing and demand in the wholesale market and the previously announced 7ACRES mechanical failure in grow rooms 1, 2 and 3. The company called this “an isolated one-time event with all three grow rooms recommissioned and replanted in September 2019.”

“Today, with Supreme Cannabis firmly established as one of the world’s fastest-growing, premium plant driven-lifestyle companies and our industry entering its second phase, the Board determined that the company would benefit from leadership with the skills and experience to accelerate our growth and transformation into a leading cannabis CPG company,” Supreme Cannabis Board Chairman, Michael La Brier said. “We are fortunate to have Colin Moore stepping up to serve as our Interim CEO and lead our efforts to drive long-term, profitable growth and shareholder value during this transitional period.”

Supreme said it is in the process of engaging a search firm to identify and evaluate a new CEO to lead Supreme Cannabis in its next phase of profitable, long-term growth.

La Brier added, “Colin’s 40 years of experience driving growth and efficiencies in branded, consumer-facing industries, including as President of Starbucks Coffee Canada, in addition to his deep knowledge of the business and strong ties with the management team, will be essential to accelerating our momentum during this important and transformative period.”

“Supreme Cannabis has built a strong foundation for the future, including award-winning premium brands that are recognized coast-to-coast, industry-leading quality and dedication to operational excellence, and committed, talented people. Going forward, we have a tremendous opportunity to drive profitable growth and cash flow by expanding our market position across all market segments and with new strains and product forms,” said Colin Moore, Interim CEO and Director.” Greater efficiencies and speed to market will come by rightsizing our production, overhead and capital. As we begin the search for the Company’s next leader, I’m excited to get to work immediately on these priorities with a great team that is committed to delivering on Supreme Cannabis’s great potential.”

Debra BorchardtDebra BorchardtJanuary 6, 2020


Emerald Health Therapeutics, Inc. (TSXV: EMH)(OTCQX: EMHTF) has agreed to the second tranche of funding for the company for approximately $4.5 million. At the end of December, the company closed on the initial tranche of a private placement that was announced on December 16, 2019. The initial tranche was for gross proceeds of $1.5 million issued at a price of $0.29 per unit.

The second tranche was also issued at a price of 29 cents per share. The company was lately trading at roughly 25 cents per share. The private placement is set to purchase 10,344,827 units of Emerald for total gross proceeds of $3 million. The company said that these units will represent the remainder of the financing previously announced on December 16, 2019, however, the securities to be issued under the Offering will be offered by way of a shelf prospectus supplement to be filed in all of the provinces of Canada pursuant to National Instrument 44-102 – Shelf Distributions and will not be subject to a hold period.

Each Unit will consist of one common share of Emerald and one common share purchase warrant. Each warrant will entitle the Investor to acquire one common share of Emerald at a price of $0.385 per Warrant Share for a period of five years following the closing of the Offering.

The company said it plans to use the net proceeds for general working capital purposes and it is expected to close on or about January 13, 2020. Emerald also said it has also reached an agreement with the holder of the Convertible Debentures issued on September 10, 2019, to settle accrued interest on the Convertible Debentures to December 31, 2019, in the amount of $383,562 by issuing an additional 1,322,627 Common Shares (the “Debt Shares”) at a deemed value of $0.29 per share. The Debt Shares will also be qualified under the Prospectus Supplement. Issuance of the Debt Shares is subject to the approval of the TSX Venture Exchange.

Debra BorchardtDebra BorchardtJanuary 2, 2020


Harvest Health & Recreation Inc. (CSE: HARV)(OTCQX: HRVSF) is buying MJardin’s (OTC: MJARF) 32,000 square foot cultivation facility in Cheyenne, Nevada in a transaction valued at $35 million. Harvest Health said it was being financed by an existing Harvest lender. The company said that $30 million was funded on December 31st with the remaining $5 million to be paid when the deal is closed.

“We expect this opportunistic acquisition to support our expanding retail asset base in Nevada and afford higher margins and profitability through vertical integration with some of our pending acquisitions in the state,” said Harvest CEO Steve White. Harvest sees the deal as a way to help it reach profitability quicker. For MJardin, it had just begun making revenue on its Cheyenne property, while Colorado continues to be its biggest source of revenue.

“We are pleased with the return on our investment at Cheyenne. The proceeds from the Transaction significantly reduce our debt while strengthening our financial position towards funding our working capital requirements in 2020,” said Pat Witcher, President, and CEO of MJardin. “We are starting the new year on a stronger footing with a clear view of accomplishing our profitability targets based on all of our key assets coming online.”

In November, the company reported revenue of $7.6 million and a net loss of $3.6 million in the second quarter. At the time Witcher said, “We further reduced SG&A and have decreased those costs by 45% compared to Q2 2019. This allows us to focus on and effectively allocate resources to developing our product lines within Health Canada’s upcoming regulations around extraction, edibles, and topicals. We continue to invest in these business lines on both sides of the border. Responsible deployment of capital to maximize shareholder value remains our top priority as we grow our operational footprint with accelerated revenue growth.”

MJardin took on corporate cost-cutting measures late in the first quarter of 2019 and the company said the resulting expected annual SG&A and payroll expense run rate was expected to be approximately $12.1 million. On May 29, 2019, MJardin said it amended the terms of its existing loan with the senior lender to remove the callable feature and convert it into a term loan, this enabled MJardin to simplify the Company’s capital structure and fully focus on executing the operational plan.


Debra BorchardtDebra BorchardtDecember 31, 2019


Cannabis stocks may have had a tough year in 2019, but it seems there is still plenty of money that wants into the space. Evidence of this was TerrAscend Corp.’s (CSE: TER) upsizing of its private placement from $24 million to $30 million. The deal is expected to close on January 7.

The previously announced private placement was said to have generated strong investor interest and oversubscribed demand. The company said that $30 million has been fully allocated and is anticipated to close in two tranches.

TerrAscend said it will use the proceeds from the Private Placement to accelerate the completion of its New Jersey cultivation and processing facilities, to satisfy the previously announced January 2020 contingent purchase price payment related to the acquisition of Ilera Healthcare, and for working capital and general corporate purposes.


The company closed the first tranche of the Private Placement, issuing 12,968,325 Units at an issue price of CAD$2.45 per Unit resulting in proceeds to the Company of CAD$31,772,412.   Each Unit consists of one common share in the capital of the company and one common share purchase warrant. Each Warrant will be exercisable to acquire one Common Share prior to January 14, 2022 at an exercise price of CAD$3.25 per Warrant Share.

The company has received subscriptions for the entire $30 million, including significant participation from Chairman Jason Wild, Executive Chairman Jason Ackerman, and all of the Company’s additional directors.

Ilera Healthcare

Ilera currently operates a retail dispensary in Plymouth Meeting, PA, with plans to open two additional dispensary sites in the Philadelphia area within the next six months. The operations include a 67,000 square foot site for cultivation and processing in Waterfall, PA with planned expansion to over 120,000 square feet in 2020. In addition to selling its products in its own dispensary, Ilera distributes its dried flower, concentrates, tinctures, and topicals to over 60 dispensaries throughout Pennsylvania. Ilera’s current revenue run-rate is over US$43 million, up from total sales in 2018 of less than US$8 million.

Currently, the Pennsylvania medical marijuana program has more than 180,000 registered patients and 20,000 registered caregivers as of August 2019 and covers 23 qualifying medical conditions including anxiety disorders, cancer, and opioid use disorder.


Debra BorchardtDebra BorchardtDecember 31, 2019


1933 Industries Inc.  (CSE: TGIF) (OTCQX: TGIFF) announced its first-quarter 2020 financial results for the period ended October 31, 2019. Total revenues for the quarter for 1933 were $3.9 million, down 26% from its previous quarter, mainly due to the decline in market share for vape and distillate sales in the recreational market in Nevada. The company said that vaping accounts for 25% of cannabis sales in Nevada while the nationwide decline was 15% during the first week of September, at the state level, Nevada saw a drop of 32% in vape sales.

The net loss for the quarter was $3.8 million, which was lower than the fourth-quarter net loss of $5.6 million. 1933 said in a statement that the decrease in the net loss was due to company-wide cost-cutting measures in order to cut expenses. “All non-essential consulting services were cut as the company remains committed to achieving profitability and increasing shareholder value. Adjusted EBITDA loss was $1.8 million for Q1 2020 compared to $1.0 million for Q1 2019. Expenses were $5.9 million for Q1 2020 and $4.7 million for the same period in 2019.”

“Company revenues for Q1 2020 were impacted by lower than expected sales from vape products, largely attributed to the rampant use of vitamin E acetate in black market products,” said 1933 CEO Chris Rebentisch. “Despite weakness in this segment, we anticipate a recovery in vape sales across both our AMA and Infused subsidiaries as well as the demand in the supply chain for distillate normalizing in Nevada in early 2020. With over 100+ SKUs across 5 product lines as intellectual property and 8 licensing partners, we believe that our diversified product portfolio and product mix will aid us in sustaining our future growth.”

He went on to add, “Cannabis sales continue to remain strong in Nevada, reaching $639 million in its fiscal year ended June 30, while 80% of sales occur in Clark County, according to the Nevada Department of Taxation figures. Over the last two years of operations, we have built AMA and Canna Hemp into valuable and respected brands, we have attracted the top brand names in the industry as our partners in Nevada, and we are expanding our physical footprint to build a sustainable foundation for growth. Our current cash position allows us to continue our operations, service debenture interest obligations and fund our capital needs. We are confident that we will achieve significant growth in 2020, driven by our expanded cannabis production in Nevada, our near-term entry into the California market, increased distribution into new markets for our Canna Hemp line and the development of products in support of our licensing agreements.”

December Moves

It was a busy month for 1933 even after the quarter ended. The company announced the execution of a two-year licensing agreement AMA and The Pantry Company Inc. in which the company will begin the buildout of a GMP-approved commercial kitchen, to be located in its extraction facility in Las Vegas, Nevada. Then 1933  announced a second licensing agreement with OG DNA Genetics. The agreement will grant 1933 Industries license to the DNA brand for the production and sale of hemp-derived CBD products.

Debra BorchardtDebra BorchardtDecember 30, 2019


C21 Investments Inc. (CSE: CXXI)(OTCQB: CXXIF) delivered unaudited financial results for the third quarter of fiscal 2020 ending October 31, 2019 with revenue of $10.58 million, a sequential increase of 7.5% over the second quarter and a big jump over last year’s $305,011 for the same time period. The net loss for C21 was $5.1 million for the third quarter.

“We delivered impressive third-quarter results reflective of the significant progress we made toward our strategic objectives. We rationalized our operations, achieved improved efficiencies, and have sharpened our focus on leveraging the strong brand awareness of our product portfolio. The positive changes we are making better position C21 for success over the long-term,” said Sonny Newman, President, and CEO, C21 Investments.

The company has seen success in its Nevada operations, while Oregon has had to restructure. Oregon reported a net loss of $6.5 million, while Nevada delivered a net profit of $5.6 million.


The company reported 172,694 customer transactions in the third quarter at Silver State Relief dispensaries, an 8% increase over Q2, and a 24% increase from Q1. Year-to-date customer transactions now exceed 580,000. C21’s Q3 market share now represents 5% of the total State of Nevada cannabis sales.

C21 said that it continues to leverage the vertical integration of its businesses by bringing our strong Oregon brands online in Nevada, which now include Phantom Farms CBD line of products, pre-rolls, with Phantom flower awaiting state approval of packaging.


C21 Investments undertook an appraisal of the Oregon leaseholds and real estate assets, which resulted in a write-down of $4.2 million in the quarter. This one-time charge reduced the quarter’s earnings per share by 5 cents to ($0.06).

“Strategically we set a course to become an efficient and profitable business with strong fundamentals. This has resulted in significant growth in adjusted EBITDA and operating cash flow results for the quarter, positioning the company to become profitable in the near term,” said Michael Kidd, Chief Financial Officer, C21 Investments.


The company noted it is involved in two different lawsuits.

A complaint was filed in the Oregon State Circuit Court for Clackamas County, on April 29, 2019, by two
current owners of Proudest Monkey Holdings, LLC (the former sole member of EFF), alleging
contract, employment, and statutory claims with an amount in controversy of $1,837,500 against the
Company, its wholly-owned subsidiaries 320204 US Holdings Corp, EFF, Swell Companies Limited, and
Phantom Brands LLC, in addition to three directors, two officers, and one former employee. The Company
and the other defendants wholly deny the allegations and claims made in the lawsuit and is defending and may
counterclaim through the lawsuit. As a procedural update, the Company has filed an Oregon Rule of Civil
Procedure (ORCP) 21 motion to dismiss all of the Plaintiffs’ claims against it, its wholly-owned subsidiaries,
and other defendants; the Rule 21 motions are pending before the court. Further, the Company’s recent
internal investigation, findings and self-reporting of actions and alleged malfeasance by the Plaintiffs at the
EFF facility (discussed more fully below under Oregon Compliance) should serve to bolster the Company’s
defense and potential counterclaims in the litigation. Given that this legal proceeding is in a premature stage
and the Company wholly denies the claims, no provision was recorded

On or about May 30, 2019, Wallace Hill filed a civil claim in the Supreme Court of British Columbia alleging
breach of contract and entitlement to 1,800,000 common shares of the Company, fully vested by March 1,
2019, and damages due to the lost opportunity to sell those shares after such date for a profit. On June 23,
2019, the Company circulated a letter to Wallace Hill terminating the agreement and accepting Wallace Hill’s
repudiation of the agreement based on Wallace Hill’s previously published defamatory comments and
termination of the agreement. Also, on June 23, 2019, the Company filed its response to the civil claim
denying all claims and filed counterclaims alleging breach of contract, a declaratory judgment of termination
of the agreement, defamation and an injunction from further defamatory comments. The civil action is
pending, and it is too early to predict its resolution.

Debra BorchardtDebra BorchardtDecember 30, 2019


It might have been a tough year for the cannabis company stock valuations, but it was a stellar year for new luxury products. Whether it was well-designed pipes or artistic accessories, consumers had their choice of high-end paraphernalia.

Puffco Travel Pipe

Puffco has won numerous awards for its vaporizer, but really the company should be winning for its industrial design of the Peak Travel Glass. This beautifully shaped water pipe lets consumers travel safely with the glass pipe filled with water, making it easier than ever to consume on the go and sure to make you the hit of any party. The company has filed for a patent on the closure system that features two positions accessible simply by rotating the mouthpiece. The open position lets you fill with water, inhale, empty water, and clean, where the closed position locks in your water so that none escapes during storage and transport.

At just under $125, this is truly a wish list item. However, it isn’t just any old water pipe. This one can be charged in order to determine heat settings. The website has created how-to videos in case you need some pointers. It’s fantastic to look at and impressive to use.

Vessel Vaporizor

Vessel Brands makes some of the most stylish vape products on the market. Designed with high-end materials like matt finished metals or woods like walnut and beechwood.  The idea is to provide the consumer with a vape product that will give the best airflow possible with an aesthetically pleasing appearance. It’s designed with a long-lasting battery that fits a standard 510 threaded oil cartridge. Each Vessel comes with a charger that has a magnetic connection on one end and a USB charger on the other. A moderate user can get 2-3 weeks from one charge.

Each Vessel is currently retailing for $80, but a special is running to get two Vessels for $125. With some vape pens, the consumer has to pull and pull, but with the vessel, it is effortless. The company is aware of the dangers that some users have been subjected to as a result of black market vape cartridges. Vessel has included several articles in its blog section in order to educate consumers on buying the safest cartridges to use with their brand. CBD oil cartridges can also be used with Vessels in case the consumer is a medical marijuana patient.

Greenlane’s Keith Haring Glass

This fall e-commerce company Greenlane (NASDAQ: GNLN) released its first products from its exclusive glass line featuring artwork by the famous late Keith Haring. Greenlane is mostly known for selling other company’s products like Juul and Pax, however, the company also has a brick and mortar store called Higher Standards. The store is known for its premium smoking accessories and it stocks the Keith Haring line. Greenlane is releasing a handful of the products at a time.

The small glass pipes or spoons retail for $50, while the larger water pipe goes for $220. At 12.4-inches tall, it is made from thick borosilicate glass that withstands extreme heat. A seven-slit showerhead percolator produces fine bubbles to moisturize, clean, and cool your smoke. The Water Pipe is designed with a fat-lipped mouthpiece, built-in ice catcher, and splashguard for comfortable draws. Trays and ashtrays retail for $60 and coming soon, lighters emblazoned with Haring artwork.

Debra BorchardtDebra BorchardtDecember 27, 2019


MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF) announced the execution of term sheets for non-core asset sales and the company also said that it executed the definitive subscription agreements for its previously-announced equity placement. Altogether, MedMen said it expects to generate gross cash proceeds of approximately $74 million.

MedMen took steps last month to cut costs which included laying off of 190 employees or 20% of its workforce and cutting back on store openings. In addition to those moves, the company also said it was going to sell assets.

Selling Licenses

This update on that announcement noted that the company has executed a non-binding term sheet for the sale of its Arizona licenses, which include three vertically-integrated licenses, and a binding term sheet for the sale of a cultivation and manufacturing license in Illinois.

MedMen said it expects to get roughly $54 million in cash proceeds through the divestiture of the non-core licenses. The completion of the sale of Arizona licenses is subject to due diligence, the execution of definitive documentation and customary regulatory approvals. The completion of the sale of the Illinois license is subject to the execution of definitive documentation and customary regulatory approvals.

The company said it will continue to explore the sale of other non-core assets and will focus on deepening its retail market share in California, Nevada, Florida, Illinois, Massachusetts, and New York.

Voting Shares Sale Reduced

The company had originally said it was selling some of its Class B subordinate voting shares for approximately $27 million at a price per share of $0.43. However, since the sale of the licenses was moved up, the company decided to reduce the number of shares down to just $20 million. Instead, MedMen will only offer 46,962,648 Class B subordinate voting shares, at a price of $0.43 per share.

Proceeds raised from the Equity Placement are contemplated to be used to finance working capital requirements and to execute on the Company’s retail footprint expansion plans in its core geographic markets.

Debra BorchardtDebra BorchardtDecember 26, 2019


HEXO Corp. (NYSE: HEXO) has entered into a definitive agreement with institutional investors for the purchase and sale of 14,970,062 common shares at an offering price of $1.67 per share for gross proceeds of $25 million. Hexo said it plans to use the proceeds from the offering for working capital and other general corporate purposes, including funding its research and development programs. It is expected to close the offering by December 30.

The stock plunged by over 16% in early trading to lately sell at $1.64. Prior to the announcement, the stock closed at $1.96. HEXO has also agreed to issue to the investor’s common share purchase warrants to purchase 7,485,032 common shares of the Company. The warrants will have a five-year term and an exercise price of $2.45 per share.

Hexo has had a pretty difficult couple of months as 2019 closed down. The company reported last month that the net revenue in the first quarter decreased sequentially to $14.5 million versus $15.4 million in the fourth quarter of 2019.

The net loss for the quarter was an eye-popping $62.4 million. The company attributed the increase in loss to “The larger magnitude of the company’s operations, the expanding scale production and sales in the period, and an impairment loss.” Operating expenses increased from $22 million in the first quarter of 2019 to $35.1 million for the first quarter of 2020.

In addition to the declining sales, Hexo disclosed on November 15, 2019, that there was a licensing issue in Block B of its Niagara facility, inventory from Block B was quarantined and held back from sales. The inventory was kept on the books and although destruction was a possible outcome, Hexo has said it has reassessed any risks related to such inventory and concluded that it is cleared for sale and will not be subject to destruction. Block B is now fully Licensed by Health Canada.

Securities lawyers smelling blood have begun looking for investors wanting to sue the company.

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 2 hours

We’ve been providing a free legislative tab on our website. Should we keep it?

@GreenMarketRpt – 1 day

⁦@hellofyllo⁩ Acquires ⁦@CannaRegs⁩ To Create Data Powerhouse. Congratulations to Amanda, a lovely person and good…

@GreenMarketRpt – 1 day

Welcome to a new feature. The Friday Book Club. Every Friday we will feature a book. This week’s Friday Book R…

Back to Top

You have Successfully Subscribed!